Giulio Metro, MD
Department of Medical Oncology, Santa Maria della Misericordia Hospital, Perugia, Italy
Research interests: treatment of thoracic malignancies (focusing on the mechanisms of resistance/sensitivity to anticancer therapies in non-small cell lung cancer)
Giulio Metro, MD is a staff physician in the Medical Oncology of the Santa Maria della Misericordia Hospital in Perugia, Italy. Dr. Metro is mainly involved in the treatment of thoracic malignancies, while his clinical research focuses on the mechanisms of resistance/sensitivity to anticancer therapies in non-small cell lung cancer.
Dr. Metro has earned his medical degree and completed the postgraduate training in Medical Oncology at the University of Rome ‘La Sapienza’. After that, he worked as consultant in the Regina Elena Cancer Institute in Rome and attended a one year internship in the Thoracic Oncology Clinical Research Program at Moffitt Cancer Center in Tampa, Florida, U.S.A..
In 2016 he earned the Master Degree in “Preclinical Drug Development: Scientific Regulatory and Ethical Aspects” at the ‘Catholic University’ Medical School of Rome, while in 2021 he obtained a Master Degree in “Immuno-oncology” at the University of Rome ‘La Sapienza’.
Since 2003, Dr. Metro is member of ESMO (European Society of Medical Oncology), where he served as committe member of the ESMO examination working group, and AIOM (Associazione Italiana di Oncologia Medica), where he held the position of scientific secretary of national guidelines on lung tumors.
Dr. Metro is Professor of Medical Oncology both in undergraduate course of biomedical laboratory techniques and in nursing school at the University of Perugia. Dr. Metro also teaches Medical Oncology and Palliative Care in the second cycle degree programme in Nursing and Midwifery Sciences at the University of Perugia.
Dr. Metro has (co-)authored several publications in peer reviewed journals and has acted either as co-investigator or principal investigator for a number of clinical trials exploring novel treatments for lung cancer.
He is Italian mother tongue and speaks fluent English.
Editorial Board Member of JCPR
Terms of Appointment: Apr 2021 - Mar 2023
Updated on April 21, 2021